Ophthalmology

Automated analysis of microaneurysm (MA) turnover predicted the development of clinically significant macular edema (CSME) among patients with mild nonproliferative diabetic retinopathy (MNDR)….

Researchers found that ranibizumab (Lucentis) may slow the progression of diabetic retinopathy….

Aggressive treatment with ranibizumab during year 3 may be more effective for diabetic macular edema (DME) than less-intensive treatment, according to 3-year outcomes from an ongoing randomized published clinical trial….

Last week, the new drug Lucentis was approved to treat diabetic macular edema…. 

Vascular Endothelial Growth Factor (VEGF) Trap-Eye provided a significant benefit to patients with diabetic macular edema in a phase II trial – and updated data now shows the initial improvements were sustained or increased a year later….

Arterial narrowing in retina seen as independent risk factor with type 1 diabetes…. 

Patients headed toward blindness because of diabetic macular edema showed substantial gains in visual acuity after two years of treatment with the angiogenesis inhibitor drug ranibizumab (Lucentis), its manufacturer said….

Study shows around 40% of ranibizumab patients substantially improved vision by 10 letters or more on an eye-chart, compared to 16% with laser therapy alone…. 

Treatment with the glitazone class of diabetes drugs leads to a “modest” increase in the risk of diabetic macular edema (DME)-a common complication that can lead to

Vision loss is nearly twice as common among U.S. adults with diabetes as those without diabetes and people with diabetes also have increased rates of glaucoma and cataracts, both of which can lead to vision loss.